ALK Abello rises as it releases 2019 report

5 February 2020

Shares of Danish allergy immunotherapy specialist ALK Abello (ALKB: DC) were up more than 9% at 1,964 Danish kroner by late morning, as the company released its annual report for 2019, saying it reached 11% growth in 2019 and closed the year ahead of schedule with its strategic transformation plan, targeting sustainable double-digit growth and earnings on a par with the specialty pharma sector. The fourth quarter continued the positive momentum seen in previous quarters, so that revenue and earnings ended at the upper end of the most recent guidance range.

Revenue for full-year 2019 increased 11% in local currencies and 12% in reported currency to DKK 3,274 million kroner ($485.6 million). Sales of tablets grew by 45%. Earnings before interest, taxes, depreciation and amortization (EBITDA) improved by 77% to 241 million kroner due to revenue growth, better margins and efficiencies.

Q4 2019 performance

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK